Decoy Therapeutics Inc.

Decoy Therapeutics Inc.

DCOY - Insider Information

Get informed when a big investor buys or sells

+ Follow
Market Cap$701.21K
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Decoy Therapeutics Inc.Decoy Therapeutics Inc.0--364%-0.6

Insider Trades

Loading insider trades…

Congress Trades

Loading congress trades…

Share Statistics

Market cap$701,207.00
Enterprise Value$-4,776,343.00
Earnings per Share$-25.99
Beta0.58
Outstanding Shares845,439

Return

Return on Equity-364.33%ROE
Return on Assets-188.37%
Return on Invested Capital-373.39%

Valuation & Multiples

P/E Ratio-0.03P/E Ratio
PEG-0.01PEG
Price to Sales-Price to Sales
Price to Book Ratio0.17Price to Book Ratio
Enterprise Value to Revenue-16.13
Enterprise Value to EBIT0.29
Enterprise Value to Net Income0
Total Debt to Enterprise-0.54
Debt to Equity0.59Debt to Equity

Revenue Sources

No data

Last Earnings Call

Report Date
November 13, 2026
EPS Estimate
-$2.59
Consensus analyst estimate
Revenue Estimate
-
Consensus analyst estimate

Next Earnings Call

Expected Date
March 29, 2027
EPS Estimate
-$1.11
Consensus analyst estimate
Revenue Estimate
-
Consensus analyst estimate

Institutional Put/Call Ratio

Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.

Put/Call Ratio0.00000%
Total Calls-
Total Puts-

Institutional Ownership

Holdings and activity of institutional investors.

Ownership %8.34%▲ 7.53%
Total Invested$87,429▲ 181.67%
Investors Holding5▲ 1.00%

About Salarius Pharmaceuticals Inc

11 employees
CEO: David Arthur

Based in Cambridge, Massachusetts, Decoy Therapeutics Inc. is an early-stage biotechnology firm dedicated to tackling critical unmet medical needs. The company employs cutting-edge machine learning and AI technologies, alongside accelera...